Alexandria reports EGP 524.80 million profit: what it means for Alexandria Pharmaceuticals stock

Published on 10/19/2026 at 02:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Audited profit reached EGP 524.80 million in fiscal year 2025/2026, up 34.16 percent. Alexandria Pharmaceuticals stock has an EGP 1,987.00 high.

Profit growth and valuation

Audited profit reached EGP 524.80 million for the fiscal year ended June 30, 2026.
Profit increased 34.16 percent from EGP 391.17 million in the preceding fiscal year.
Alexandria Pharmaceuticals stock was last at EGP 1,408.31 on October 14, 2026, below its EGP 1,987.00 52-week high.

AXPH, EGS38341C011, Illustration mit AI erstellt.

Alexandria Pharmaceuticals (EGS38341C011) reported audited profit of EGP 524.80 million for the fiscal year ended June 30, 2026. According to FoudaLens on September 28, 2026, the result compared with EGP 391.17 million for the preceding fiscal year and represented growth of 34.16 percent.

What does profit growth mean?

The headline figure gives Alexandria Pharmaceuticals a clear earnings reference for the stock. The comparison is based on audited results for two consecutive fiscal years, rather than on a market estimate or a forward projection. That distinction matters because the reported profit is an actual result for the company, while the share price reflects expectations about future earnings.

The company operates in pharmaceuticals and related products for human and veterinary use. MarketWatch describes Alexandria Pharmaceuticals as a manufacturer and trader of pharmaceutical products, dietary supplements, cosmetics and related raw materials. Its business profile therefore spans more than one product category, while the latest audited result provides the central quantified measure.

Stock stays below yearly high

The market picture is more restrained than the annual earnings comparison. The Egyptian Exchange quotation was last at EGP 1,408.31 on October 14, 2026, against a 52-week high of EGP 1,987.00 and a 52-week low of EGP 701.66. The distance between the latest quotation and the high leaves the share price below its yearly peak, even as the fiscal-year profit comparison remained positive.

For investors, the useful reading is the combination of a 34.16 percent year-over-year profit increase and a share price that has not returned to its yearly high. The next valuation question is whether future disclosures can sustain the EGP 524.80 million earnings base reported for fiscal year 2025/2026.